<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033054</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2021-0492</org_study_id>
    <nct_id>NCT05033054</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Magnesium Supplementation vs. Dapagliflozin in Patients With Diabetic Kidney Disease (DKD)</brief_title>
  <official_title>Effect of EffCaMgCit vs. SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized double blind placebo controlled parallel group trial to&#xD;
      assess the effect of Effervescent calcium magnesium citrate (EffCaMgCitrate) and&#xD;
      dapagliflozin on surrogate markers of kidney and cardiovascular health in patients with stage&#xD;
      3b-4 Chronic Kidney Disease (CKD).&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
        1. Placebo EffCaMgCitrate + Placebo Dapagliflozin BID (bis in die / two times)&#xD;
&#xD;
        2. EffCaMgCitrate 480mg Mg (total dosage per day) + Placebo Dapagliflozin BID&#xD;
&#xD;
        3. Dapagliflozin 10mg (total dosage per day) + Placebo EffCaMgCitrate BID&#xD;
&#xD;
      This study includes three clinic in person visits and weekly telephone visits for 24 weeks.&#xD;
&#xD;
        1. Recruit 30 patients with CKD stages 3b-4 and randomize them in double-blind fashion to&#xD;
           either placebo, CaMgcitrate 480mg Mg or dapagliflozin 10mg twice daily for 24 weeks&#xD;
&#xD;
        2. Determine the effect of interventions on the primary outcome variable serum klotho&#xD;
           measured by immunoprecipitation-immunoblot&#xD;
&#xD;
        3. Determine the effect of interventions on magnesium.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum klotho levels at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in serum klotho levels in participants with advanced Diabetic Kidney Disease (DKD) at 12 weeks are measured by immunoprecipitation-immunoblot.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum klotho levels at 24 week</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>Change in Serum klotho levels in participants with advanced Diabetic Kidney Disease (DKD) at 24 weeks are measured by immunoprecipitation-immunoblot.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum magnesium levels at 12 weeks</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Mean change from baseline in serum magnesium levels at 12 weeks is measured. Serum magnesium levels are measured by measuring the level of magnesium in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum magnesium levels at 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>Mean change from baseline in serum magnesium levels at 24 weeks is measured. Serum magnesium levels are measured by measuring the level of magnesium in the blood.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Kidney Disease, Chronic</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo EffCaMgCitrate + Placebo Dapagliflozin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 1 will receive a Placebo form the Effervescent CaMgCitrate and a Placebo form of the Dapagliflozin twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: EffCaMgCitrate + Placebo Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will receive the medication EffCalMgcitrate 480mg (total dosage per day) and Placebo Dapagliflozin twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Dapagliflozin + Placebo EffCaMgCitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 will receive the medication Dapagliflozin10mg (total dosage per day) and Placebo Effervescent CaMgCitrate twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EffCaMgCitrate 480 mg</intervention_name>
    <description>Effervescent calcium magnesium citrate ( EffCaMgCitrate) is a powder mixture of calcium carbonate, trimagnesium dicitrate, and citric acid monohydrate, to be ingested orally after dissolving in water twice daily.</description>
    <arm_group_label>Group 2: EffCaMgCitrate + Placebo Dapagliflozin</arm_group_label>
    <other_name>dietary magnesium supplementation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 mg</intervention_name>
    <description>Dapagliflozin tablets containing 10 mg will be administered orally with 8 oz water.</description>
    <arm_group_label>Group 3: Dapagliflozin + Placebo EffCaMgCitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo EffCaMgCitrate</intervention_name>
    <description>Placebo Effervescent calcium magnesium citrate ( EffCaMgCitrate) (480mg) to be ingested orally after dissolving in water twice daily.</description>
    <arm_group_label>Group 1: Placebo EffCaMgCitrate + Placebo Dapagliflozin</arm_group_label>
    <arm_group_label>Group 3: Dapagliflozin + Placebo EffCaMgCitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Dapagliflozin</intervention_name>
    <description>Placebo Dapagliflozin tablets (10 mg) will be administered orally with 8 oz water.</description>
    <arm_group_label>Group 1: Placebo EffCaMgCitrate + Placebo Dapagliflozin</arm_group_label>
    <arm_group_label>Group 2: EffCaMgCitrate + Placebo Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years of age&#xD;
&#xD;
          -  All races and ethnicities&#xD;
&#xD;
          -  All genders&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  History of hypertension defined as &gt; 130 or &gt; 80 mmHg or normotensive on pharmacologic&#xD;
             therapy&#xD;
&#xD;
          -  Estimated glomerular filtration rate (GFR) (CKD Epi equation) of 15-44 ml/min/1.73 m2&#xD;
             (Stages 3b-4 CKD)&#xD;
&#xD;
          -  Urinary albumin creatinine ratio of &gt; 200 mg/g &lt;5000mg/g&#xD;
&#xD;
          -  Serum magnesium level at screening of &gt; 1.3 mg/dl&#xD;
&#xD;
          -  Ability of study participant or legally authorized representative to provide informed&#xD;
             written consent&#xD;
&#xD;
          -  Able to maintain stable dose of any vitamin D and any calcium supplements for 180 days&#xD;
             post randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis&#xD;
             or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis&#xD;
&#xD;
          -  Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for&#xD;
             primary or secondary renal disease within 6 months prior to enrolment&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Receiving therapy with a sodium glucose co-transporter 2 (SGLT2) inhibitor within 8&#xD;
             weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor&#xD;
&#xD;
          -  Type 1 diabetes (T1D)&#xD;
&#xD;
          -  Active use of either dapagliflozin or magnesium supplements&#xD;
&#xD;
          -  Inability to temporarily discontinue magnesium of calcium supplements&#xD;
&#xD;
          -  History of persistent hypercalcemia (serum total Calcium &gt; 10.5 mg/dl)&#xD;
&#xD;
          -  History of persistent hypermagnesemia (serum Mg &gt; 3.0 mg/dl)&#xD;
&#xD;
          -  Body mass index &gt; 45 kg/m2&#xD;
&#xD;
          -  Intolerance to magnesium supplementation&#xD;
&#xD;
          -  Active on kidney transplant list&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Any condition outside the renal and cardiovascular disease area, such as but not&#xD;
             limited to malignancy, with a life expectancy of less than 2 years based on&#xD;
             investigatorÂ´s clinical judgement&#xD;
&#xD;
          -  Active malignancy requiring treatment at the time of screening (with the exception of&#xD;
             successfully treated basal cell or treated squamous cell carcinoma).&#xD;
&#xD;
          -  Hepatic impairment (aspartate transaminase [AST] or alanine transaminase [ALT] &gt;3x the&#xD;
             upper limit of normal [ULN]; or total bilirubin &gt;2x ULN at time of enrolment)&#xD;
&#xD;
          -  Women of child-bearing potential (ie, those who are not chemically or surgically&#xD;
             sterilized or who are not post-menopausal) who are not willing to use a medically&#xD;
             accepted method of contraception that is considered reliable in the judgment of the&#xD;
             investigator or women who have a positive pregnancy test at enrolment or randomization&#xD;
             or women who are breast-feeding&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product (IP) during&#xD;
             the last month prior to Enrolment&#xD;
&#xD;
          -  Inability of the patient, in the opinion of the investigator, to understand and/or&#xD;
             comply with IP, procedures and/or follow-up OR any conditions that, in the opinion of&#xD;
             the investigator, may render the patient unable to complete the study. Patients who&#xD;
             cannot complete the patient reported outcome (PRO) assessments can still participate&#xD;
             in the study&#xD;
&#xD;
          -  Treatment with adrenocorticosteroids or aluminum-containing antacids or drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Toto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Toto, MD</last_name>
    <phone>214-645-8267</phone>
    <email>robert.toto@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natasha Wen, Bachelor</last_name>
    <phone>214-645-8240</phone>
    <email>yu.wen@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Natasha Wen, Bachelor</last_name>
      <phone>214-645-8240</phone>
      <email>yu.wen@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Robert Toto</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

